The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors.
 
Joseph W. Kim
Stock and Other Ownership Interests - ABION (I); Celgene (I); Johnson & Johnson (I)
Consulting or Advisory Role - EMD Serono; Sanofi; Voluntis
Research Funding - Immune Design
 
Navid Hafez
No Relationships to Disclose
 
Hatem Hussein Soliman
Consulting or Advisory Role - AstraZeneca; Celgene; Lilly; Novartis; Pfizer; Puma Biotechnology
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Lilly
 
Siqing Fu
Research Funding - Abbisko (Inst); Anaeropharma (Inst); Arrien Pharmaceuticals (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Hookipa Pharma (Inst); Huya Bioscience International (Inst); Immune Cell Therapy (Inst); Innovent Biologics (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Medivir (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NIH/NCI (Inst); Novartis (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); Takeda (Inst); Tolero Pharmaceuticals (Inst)
 
Shumei Kato
Honoraria - Roche
Consulting or Advisory Role - Foundation Medicine; Foundation Medicine
 
Primo Lara
Consulting or Advisory Role - CellMax Life; Janssen; Merck; Pfizer
Research Funding - Aragon Pharmaceuticals (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst); TRACON Pharma (Inst)
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Albiruni Ryan Abdul Razak
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Adaptimmune; Boehringer Ingelheim; Lilly; Merck
Research Funding - Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; Lilly; MedImmune; Merck; Novartis; Pfizer; Roche/Genentech
 
Dana Backlund Cardin
Consulting or Advisory Role - Abbvie; Rafael Pharmaceuticals
Research Funding - Advaxis (Inst); Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EMD Serono (Inst); Incyte (Inst); Lilly (Inst); Synta (Inst)
Travel, Accommodations, Expenses - Abbvie
 
Pamela N. Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics
Honoraria - AtlasMedx; Celgene; CStone Pharmaceuticals; Epigene; McVeigh; Prometheus (I); Xynomic Pharma (Inst)
Consulting or Advisory Role - HUYA Bioscience International
Research Funding - Andes Biotechnologies (Inst); Biomarin (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Intellikine (Inst); Merck (Inst); Merrimack (Inst); Nektar (Inst); Novartis (Inst); OncoMed (Inst); Onconova Therapeutics (Inst); oncosec (Inst); Pfizer (Inst); Piramal Life Science (Inst); Plexxikon (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
 
Joseph Paul Eder
Consulting or Advisory Role - Roche/Genentech
 
Elizabeth M. Swisher
Leadership - IDEAYA Biosciences
Stock and Other Ownership Interests - IDEAYA Biosciences
Research Funding - Clovis Oncology; Tesaro
 
Andrew B. Nixon
Consulting or Advisory Role - GlaxoSmithKline; Kanghong Pharma; Lilly
Research Funding - AstraZeneca/MedImmune; Eureka Therapeutics; Genentech/Roche; HTG Molecular Diagnostics; Leadiant Biosciences; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
Travel, Accommodations, Expenses - TRACON Pharma
 
Abhijit Patel
Stock and Other Ownership Interests - Binary Genomics
Honoraria - NuGEN
Consulting or Advisory Role - NuGEN; NuProbe
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Inventor and assignee of patents and patent applications covering ultra sensitive nucleic acid analysis technologies.
Travel, Accommodations, Expenses - NuGEN; Statum Fund
 
Yu Shyr
Consulting or Advisory Role - Aduro Biotech; GlaxoSmithKline; Janssen Research & Development; Novartis; Pfizer; Roche/Genentech
Patents, Royalties, Other Intellectual Property - Royalty for TNBCType for Insight Genetics. TNBCType is a web-based subtyping tool TNBCtype for candidate TNBC samples using our gene expression meta data and classification method.
 
S. Percy Ivy
No Relationships to Disclose
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; Agenus; Agios; Astellas Pharma; AstraZeneca; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-MAB; Immunome; IQvia; Macrogenics; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; Sotio; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech